GSK to showcase latest research at the International RSV Symposium to advance RSV prevention in adults: London, UK Saturday, March 8, 2025, 14:00 Hrs [IST] GSK plc will share its ...
New findings from a recent white paper highlight the economic and healthcare burden posed by Respiratory Syncytial Virus (RSV ...
GSK has become the first pharma company to get regulatory approval for a vaccine against respiratory syncytial virus (RSV), setting up what looks set to be a highly lucrative – and likely ...
Already competing to bring the first vaccine against respiratory syncytial virus (RSV) to market, Pfizer and GSK are also fighting a patent infringement battle in the courts. Earlier this month ...
PHILADELPHIA, June 07, 2024--US FDA approves expanded age indication for GSK’s AREXVY, the first respiratory syncytial virus (RSV) vaccine for adults aged 50-59 at increased risk Strategic ...
Investing News Network on MSN2d
Bird Flu Vaccine Stocks: 8 Companies Developing H5N1 VaccinesLife science companies developing bird flu vaccines are gaining attention as the avian influenza subtype H5N1 becomes an ...
Five years after the start of the pandemic, the fight over who owns the underlying technologies that made the Covid-19 ...
Investor's Business Daily on MSN6d
Why Moderna Stock Has Surged 15% This Week Despite Mixed NewsModerna stock has surged more than 20% this week after regulatory filings showed several executives bought shares on the open ...
MANILA, Philippines — Respiratory Syncytial Virus (RSV) is a common, contagious virus affecting the lungs and breathing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback